Recent studies suggest that early lung inflammation may play an important role for hypoxic respiratory failure in infants with MAS. To study whether early D therapy would improve clinical course and outcome, a double-blind randomized trial was undertaken on 50 infants (23 saline control C, 27 D) who had severe MAS (by X-Ray and by clinical RDS score of Downes et al > 6). Dexamethasone 1.0 mg/kg iv shortly after birth and then 0.5 mg/kg/dose q.12.h. on day 1-3; 0.25 mg/kg/dose q.12.h. on day 4-7. All infants had ET suction at birth. Both C and D had comparable B.W. (mean±SD 3.0±0.5 vs. 3.0±0.6 kg), G.A. (39.2±1.4 vs. 39.4±1.9 wk), Apgar score at and incidence of fetal distress. The first dose of D was given at 9.9± 8.3 hrs. (*p<.05, **p<.01) Table

Table 1 No caption available.
Full size table

More infants in C than in D remained intubated after d-3. Significantly lower PCO2 and higher pH were seen in D than in C on day 2-4 and day 3-4 respectively. Resp. set-up and FIO2, PO2 were comparable between the groups during the study. Infants in D required sign. (p<.05) shorter duration on IMV (3.5±3.1 d) than infants in C (4.6±3.0 d). There was no difference between the groups in mortality (C:1/23, D:2/27), CLD (C:0/23, D:0/27) and in duration of O2 therapy (C:6.6±5.8, D:7.0±4.1 d) and of hospitalization (C:14±6, D:14±5 d). A transient higher BP and glucose on day 2, 3 and on day 3, 5, 7 respectively and more weight loss on day 5 to 10 were seen in D than in C infants. We concluded that early D therapy for one week improved pul. Ventilation and facilitated weaning from IMV.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD